Rexahn Pharmaceuticals, Inc. (RNN)

Check out top investors' recommendation for RNN
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system disorders, sexual dysfunction, and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt-1, which has completed a Phase IIa clinical trial for the treatment of pancreatic cancer, as well as is focusing on initiating Phase IIa clinical trials for chemo-resistant solid tumors and hematological malignancies; RX-3117, which has completed an exploratory Phase I clinical study in humans with therapeutic potential in a range of cancers, including colon, lung, and pancreatic cancer; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase and focuses on initiating Phase I clinical trials. The company’s pre-clinical pipeline consist of RX-0201-Nano, a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, nano-polymer anticancer. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Joseph Pantginis Roth Capital Partners LLC Buy   Mar 04, '19     10.00  Mar 04, '20  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 15, '19     17.00  Jan 15, '20  N/A 
George Zavoico Mcnicoll, Lewis, & Vlak Buy   Oct 02, '18     7.50  Oct 02, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 25, '18     19.50  Sep 25, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Aug 06, '18     19.50  Aug 06, '19  N/A 
George Zavoico Mcnicoll, Lewis, & Vlak Buy   Jul 31, '18     7.50  Jul 31, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jun 04, '18     19.50  Jun 04, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Mar 12, '18     19.50  Mar 12, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 22, '18     19.50  Jan 22, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Nov 06, '17     19.50  Nov 06, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Aug 14, '17     19.50  Aug 14, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Aug 11, '17     19.50  Aug 11, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Nov 03, '15   0.49    Nov 03, '16  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 28, '15   0.53  3.00  Sep 28, '16  -58.49% 
Aneish Arora Unaffiliated Buy   Feb 15, '14   1.09  3.00  Mar 15, '14  11.93% 
Enoch Kuo Unaffiliated Sell   Apr 01, '13   0.30  0.15  Apr 01, '14  -260.00%